Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Omeprazole 40 mg Clear all
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

NCT00241553
View directory record Official record
Conditions
NSAIDs, Upper GI Symptoms
Interventions
Esomeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
31
States / cities
Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658775
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations

NCT02790840
View directory record Official record
Conditions
Healthy
Interventions
Omeprazole, Gefapixant
Drug
Lead sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis

NCT00492622
View directory record Official record
Conditions
Gastroparesis, Gastroesophageal Reflux Disease
Interventions
Immediate-release omeprazole, Delayed-release omeprazole
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects

NCT00230516
View directory record Official record
Conditions
Healthy
Interventions
Nexium, Prevacid
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 5, 2026, 9:03 AM EDT
Not listed Phase 2Phase 3 Interventional

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

NCT01089959
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
esomeprazole
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 5, 2026, 9:03 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

NCT01844583
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
Alisertib, Esomeprazole, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

NCT00206180
View directory record Official record
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Interventions
esomeprazole magnesium (oral medication)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
39
States / cities
Alabaster, Alabama • Anaheim, California • Dinuba, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 5, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional Results available

Viokase 16, Viokase16 Plus Nexium and Nexium Alone

NCT01142128
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Nexium (esomeprazole magnesium), Placebo to Nexium, Viokase 16 (pancrelipase) + Nexium, Viokase 16 + placebo to Nexium
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

NCT01766050
View directory record Official record
Conditions
Transplant Rejection
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Belatacept
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris

NCT02394340
View directory record Official record
Conditions
Tinea Pedis, Tinea Cruris
Interventions
Omeprazole 40 mg, Luliconazole Cream 1%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 5, 2026, 9:03 AM EDT
Completed No phase listed Observational Results available

Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation

NCT00584922
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Endoscopy in group I (all patients)
Procedure
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants

NCT05338502
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Ranitidine, Omeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Which Supraesophageal Reflux Symptoms Reliably Respond to Proton-Pump-Inhibitor (PPI) Therapy

NCT00170001
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Nexium, Sugar Pill
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

NCT05134350
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LOXO-305, Omeprazole
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

NCT01517399
View directory record Official record
Conditions
Solid Tumors
Interventions
tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
Drug · Dietary Supplement
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

NCT06366243
View directory record Official record
Conditions
Healthy Participants
Interventions
Emraclidine, Esomeprazole
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

NCT00317044
View directory record Official record
Conditions
Asthma, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 5, 2026, 9:03 AM EDT
Recruiting Phase 4 Interventional

The Mechanism Versus PPI Trial

NCT06999577
View directory record Official record
Conditions
Laryngopharyngeal Reflux, Cough, Throat Clearing, Dysphonia, Reflux
Interventions
Omeprazole 40 MG, Laryngeal Recalibration Therapy, GERD Lifestyle Recommendations
Drug · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 89 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Deigo, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 5, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions

NCT03234699
View directory record Official record
Conditions
Healthy
Interventions
Cenobamate, midazolam, Warfarin Pill, Omeprazole Pill, Bupropion Pill
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 5, 2026, 9:03 AM EDT